![NGS and precision oncology in Australia: insights from Profs Peter Gibbs and Svetlana Cherepanoff New Project 3 New Project 3](https://clinicalvalue.com/wp-content/uploads/2023/08/New-Project-3.png)
NGS and precision oncology in Australia: insights from Profs Peter Gibbs and Svetlana Cherepanoff
In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia.
READ MOREYou are about to leave the Clinical Value website now.
In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia.
READ MORENGS and digital applications for oncology management can help improve early cancer detection and prevention, reducing human and economic costs of the cancer. In this article,…
READ MOREComprehensive genomic profiling (CGP) is a method of cancer genomic testing used to reveal the unique set of mutations within the cancer’s DNA which determine how…
READ MOREIn this article, Dr Lam Tai-Chung shares how his institution has had first-hand experience of landmark cases and outstanding treatment responses from using NGS in seemingly…
READ MOREIn this article, Prof Jee Hyun Kim explains her clinical experiences of NGS, and how she sees it evolving within South Korea’s innovative healthcare ecosystem.
READ MOREWhile precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of…
READ MOREThis whitepaper shares recommendations on ensuring standardization and quality of NGS across the region, to realize the potential of NGS and establish more effective and market-appropriate…
READ MOREThe NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in…
READ MORE